The stock has a 36-month beta value of 0.63. Opinions on the stock are mixed, with 5 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for OTLK is 15.24M, and at present, short sellers hold a 15.93% of that float. On September 12, 2024, the average trading volume of OTLK was 197.36K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
OTLK) stock’s latest price update
Outlook Therapeutics Inc (NASDAQ: OTLK) has experienced a decline in its stock price by -9.76 compared to its previous closing price of 7.79. However, the company has seen a fall of -4.42% in its stock price over the last five trading days. globenewswire.com reported 2024-09-04 that ISELIN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced the completion of enrollment for its NORSE EIGHT clinical trial evaluating ONS-5010 in wet AMD patients. NORSE EIGHT is the subject of a Special Protocol Assessment (SPA) agreement with the FDA, and, if successful, is the final anticipated clinical trial required before expected resubmission of the Outlook Therapeutics’ Biologics License Application (BLA) for ONS-5010.
OTLK’s Market Performance
OTLK’s stock has fallen by -4.42% in the past week, with a monthly drop of -6.39% and a quarterly drop of -7.86%. The volatility ratio for the week is 8.10% while the volatility levels for the last 30 days are 6.78% for Outlook Therapeutics Inc The simple moving average for the past 20 days is -6.08% for OTLK’s stock, with a -12.70% simple moving average for the past 200 days.
Analysts’ Opinion of OTLK
Many brokerage firms have already submitted their reports for OTLK stocks, with BTIG Research repeating the rating for OTLK by listing it as a “Buy.” The predicted price for OTLK in the upcoming period, according to BTIG Research is $50 based on the research report published on March 27, 2024 of the current year 2024.
Chardan Capital Markets, on the other hand, stated in their research note that they expect to see OTLK reach a price target of $3. The rating they have provided for OTLK stocks is “Buy” according to the report published on February 15th, 2024.
OTLK Trading at -8.75% from the 50-Day Moving Average
After a stumble in the market that brought OTLK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.94% of loss for the given period.
Volatility was left at 6.78%, however, over the last 30 days, the volatility rate increased by 8.10%, as shares sank -9.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.13% lower at present.
During the last 5 trading sessions, OTLK fell by -4.42%, which changed the moving average for the period of 200-days by -21.99% in comparison to the 20-day moving average, which settled at $7.45. In addition, Outlook Therapeutics Inc saw -10.79% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OTLK starting from Haddadin Yezan Munther, who purchase 1,882 shares at the price of $11.82 back on Mar 28 ’24. After this action, Haddadin Yezan Munther now owns 5,049 shares of Outlook Therapeutics Inc, valued at $22,242 using the latest closing price.
Evanson Jeff, the CHIEF COMMERCIAL OFFICER of Outlook Therapeutics Inc, purchase 62,484 shares at $0.42 during a trade that took place back on Mar 07 ’24, which means that Evanson Jeff is holding 808,459 shares at $26,243 based on the most recent closing price.
Stock Fundamentals for OTLK
The total capital return value is set at -13.51. Equity return is now at value -827.71, with -205.48 for asset returns.
Based on Outlook Therapeutics Inc (OTLK), the company’s capital structure generated -0.64 points at debt to capital in total, while cash flow to debt ratio is standing at -1.97. The debt to equity ratio resting at -0.39. The interest coverage ratio of the stock is -0.0.
Currently, EBITDA for the company is -52.6 million with net debt to EBITDA at -0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.07.
Conclusion
To sum up, Outlook Therapeutics Inc (OTLK) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
